Stephens Initiates Coverage on IQVIA (NYSE:IQV)

Equities researchers at Stephens initiated coverage on shares of IQVIA (NYSE:IQV) in a research note issued on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $250.00 price target on the medical research company’s stock. Stephens’ price target suggests a potential upside of 30.53% from the company’s previous close.

Several other brokerages also recently weighed in on IQV. JPMorgan Chase & Co. dropped their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI reduced their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Leerink Partners reiterated an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Stock Up 0.3 %

Shares of IQV opened at $191.52 on Friday. The firm has a 50 day simple moving average of $209.54 and a two-hundred day simple moving average of $223.42. The company has a market cap of $34.76 billion, a P/E ratio of 25.13, a P/E/G ratio of 2.05 and a beta of 1.49. IQVIA has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Hedge Funds Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. lifted its position in shares of IQVIA by 702.9% in the 2nd quarter. Blue Trust Inc. now owns 281 shares of the medical research company’s stock worth $59,000 after purchasing an additional 246 shares during the period. LRI Investments LLC lifted its holdings in IQVIA by 120.9% in the second quarter. LRI Investments LLC now owns 654 shares of the medical research company’s stock valued at $138,000 after buying an additional 358 shares during the period. Cambridge Investment Research Advisors Inc. boosted its position in IQVIA by 6.8% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,119 shares of the medical research company’s stock valued at $4,888,000 after acquiring an additional 1,478 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its holdings in IQVIA by 20.6% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,967 shares of the medical research company’s stock worth $1,473,000 after acquiring an additional 1,190 shares during the period. Finally, Simmons Bank bought a new position in shares of IQVIA in the 2nd quarter worth about $203,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.